Vascarta's Curcumin Gel: A Bold Strategy for Sickle Cell's Unmet Needs

SUMMIT, NJ – June 24, 2026 – In the high-stakes world of biopharmaceutical development, press releases announcing early-stage clinical trial results are a common currency. But the latest dispatch from Vascarta Inc., a clinical-stage company, offers more than just promising data; it unveils a bold and unconventional strategy that could reshape how treatments for chronic diseases reach patients. The company today announced positive Phase I results for VAS-101, a novel curcumin-based gel for Sickle Cell Disease (SCD), a debilitating genetic disorder. While the scientific findings are intriguing, it's the company's decision to make the treatment available now—years ahead of potential FDA approval—that positions Vascarta at the intersection of innovation, patient advocacy, and calculated market disruption.

A Glimmer of Hope for Chronic Pain

For the more than 165,000 people in the U.S. living with sickle cell disease, life is often defined by pain. The genetic disorder, which primarily affects individuals of African and non-Hispanic Black descent, causes red blood cells to deform into a rigid crescent or “sickle” shape. These cells can block blood flow, leading to excruciating pain episodes known as vaso-occlusive crises (VOCs), organ damage, and a life expectancy more than 20 years shorter than the national average. For decades, treatment options have been limited, often relying on pain management with opioids and therapies that come with significant side effects.

It is this profound unmet need that Vascarta aims to address. The company’s small Phase I study, conducted with the Foundation for Sickle Cell Disease Research (FSCDR) and published in the Journal of Sickle Cell Disease, involved just five patients. Over 29 days, they received a minimal dose of VAS-101 sublingually (under the tongue). The results, while preliminary, point toward tangible patient benefits. Mean pain scores, on a 10-point scale, decreased from 7.0 to 6.6, and patients also reported feeling less fatigued and more energetic. While a modest drop, any reduction in the baseline of chronic pain is significant for this community.

“Pain remains one of the most challenging and life-disrupting aspects of this disease, and new approaches are urgently needed,” commented Dr. Lanetta Bronté, President of FSCDR. “While early in development, this research represents an important step toward finding new options that could one day help ease that burden.”

Unlocking an Ancient Remedy with Modern Tech

At the heart of Vascarta’s innovation is a modern solution to an ancient problem. Curcumin, the active compound in turmeric, is a well-documented anti-inflammatory and antioxidant. Its potential to combat the inflammation and oxidative stress central to SCD has long been recognized, but its therapeutic use has been crippled by one major flaw: extremely poor bioavailability when taken orally. The body simply doesn't absorb it well enough to have a systemic effect.

Vascarta’s VAS-101, invented by Chief Science Officer Dr. Joel Friedman, is designed to bypass this hurdle. Using a patented transdermal delivery technology, the gel allows curcumin to be absorbed directly into the bloodstream. The clinical data suggests this approach is working. Beyond patient-reported symptom relief, the study measured key functional biomarkers in the patients' red blood cells. The results showed a delay in the time it took for cells to sickle and a decrease in the overall rate of sickling. In essence, the treatment appears to be making the red blood cells more resilient.

“The preclinical and clinical results to date demonstrate pain reduction and therapeutic efficacy resulting from our novel approach of targeting red blood cell instability, neuro-inflammation and vascular inflammation,” Dr. Friedman explained. This focus on the underlying mechanics of the disease, rather than just symptom management, represents a critical shift. The study suggests that even at a low dose, VAS-101 is creating a measurable biological effect where it matters most—at the cellular level.

A High-Stakes Bet on Early Access

While the science is intriguing, it’s Vascarta’s business strategy that truly pushes the envelope. In a move rarely seen from clinical-stage biotechs, the company has already made VAS-101 (marketed as Vasceptor®) available to patients. Leveraging curcumin’s well-established safety profile, the treatment can be obtained with a doctor's prescription through a single 503A compounding pharmacy. This pathway allows pharmacists to prepare customized medications for individual patients, operating under a different regulatory framework than mass-produced, FDA-approved drugs.

Dr. Richard Prince, Vascarta's Chairman and CEO, framed the decision as mission-driven. “We are excited at the prospect of bringing relief to SCD sufferers who have limited therapeutic options,” he stated, noting the company still plans to file for a formal Investigational New Drug (IND) application with the FDA later this year to begin the traditional, years-long approval process.

This dual-track approach is a high-stakes gamble. On one hand, it provides immediate access for desperate patients and could generate early revenue and real-world data for Vascarta. The company highlighted a powerful anecdotal case of a patient whose severe, menstruation-linked SCD pain has been controlled for 12 consecutive months using the compounded gel. On the other hand, it sidesteps the rigorous, large-scale validation of safety and efficacy that the FDA process ensures, a move that will undoubtedly draw scrutiny. For investors and industry watchers, it’s a bold play that trades regulatory convention for speed-to-market and patient access.

Navigating a Crowded and Costly Market

Vascarta's strategy is unfolding against a backdrop of seismic shifts in the SCD market. In late 2023, the FDA approved two revolutionary gene therapies, Casgevy and Lyfgenia, which offer the potential for a one-time cure. However, with price tags ranging from $2.2 to $3.1 million per patient and requiring complex, high-risk procedures, these groundbreaking treatments remain inaccessible for the vast majority. This creates a massive opportunity for therapies that are affordable, easy to administer, and can improve the quality of life for the broader SCD population.

This is the economic landscape where VAS-101 could find its footing. Rather than competing with multi-million-dollar cures, it offers a potential chronic management tool that could be used by a wide range of patients to manage daily symptoms like pain and fatigue. If larger trials confirm its efficacy and safety, a cost-effective topical gel could become a new standard of care, complementing existing treatments and filling a crucial gap left by both older drugs and newer, prohibitively expensive cures.

The path forward for Vascarta is long and fraught with the typical challenges of drug development. The promising results from five patients must be replicated in hundreds, and the company's unconventional market strategy will be tested by regulators and competitors alike. Yet, by combining a natural compound with novel delivery technology and a bold go-to-market plan, the company is writing a fascinating new chapter in the fight against sickle cell disease.